ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.48
-0.64%
US Tech 100
18,124.80
-0.57%
S&P 500
5,267.84
-0.74%
US Dollar vs CAD
1.37315
0.29%
Bitcoin
67,626.61
-2.14%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Sandoz Group Ag (0SAN)

  7. Sandoz Group Ag (0SAN) News

0SAN

Sandoz (0SAN)

Sandoz Group Ag
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0SAN
DateTimeSourceHeadlineSymbolCompany
05/22/202412:00AMUK RegulatorySandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in EuropeLSE:0SANSandoz Group Ag
05/07/202412:00AMUK RegulatorySandoz reports first quarter 2024 salesLSE:0SANSandoz Group Ag
04/30/20245:25AMUK RegulatoryShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGLSE:0SANSandoz Group Ag
04/30/202412:00AMUK RegulatorySandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsLSE:0SANSandoz Group Ag
04/22/202412:00AMUK RegulatorySandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringLSE:0SANSandoz Group Ag
03/21/20248:00AMUK RegulatorySandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesLSE:0SANSandoz Group Ag
03/13/20241:00AMUK RegulatorySandoz reports fourth quarter 2023 sales and full-year 2023 resultsLSE:0SANSandoz Group Ag
03/05/202412:24PMUK RegulatorySandoz receives FDA approval for first and only denosumab biosimilarsLSE:0SANSandoz Group Ag
03/05/202412:00AMUK RegulatorySandoz announces nominations to the Board of Directors and leadership changeLSE:0SANSandoz Group Ag
03/04/202412:00AMUK RegulatorySandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US marketLSE:0SANSandoz Group Ag
02/29/202412:00AMUK RegulatorySandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffsLSE:0SANSandoz Group Ag
02/01/202412:15AMUK RegulatorySandoz announces changes in the Board of DirectorsLSE:0SANSandoz Group Ag
01/31/202412:00AMUK RegulatorySandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in GermanyLSE:0SANSandoz Group Ag
 Showing the most relevant articles for your search:LSE:0SAN

Your Recent History

BIT
P1YX05
NLBNPIT1YX05 20240522 1.8
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved